Browse the evidence

A three-week ketogenic diet (max 10% carbohydrates) significantly reduces serum insulin and triglycerides while increasing anti-inflammatory fatty acids (ETA, DHA) and ketone bodies in healthy adults.

To trigger these metabolic benefits, restrict carbohydrates to under 30g per day (approx 10% of calories) for at least three weeks. Focus on increasing fat and moderate protein intake. Monitor ketone levels to ensure you are in ketosis. This protocol significantly lowers insulin and triglycerides while boosting anti-inflammatory markers in healthy people.

Cardiac rehabilitation programs significantly improve exercise capacity, cardiovascular risk factors, and psychological well-being in obese patients, regardless of baseline cardiovascular disease status.

If you are obese, especially if you have heart issues, do not avoid exercise. Seek a cardiac rehabilitation program. These programs combine supervised exercise (aerobic and resistance), diet advice, and psychological support. They significantly improve your heart health, fitness, and mood. Start with moderate intensity and follow a personalized plan.

High-intensity physical activity (highest quartile of metabolic equivalents) and resistance/aerobic training reduce hepatic steatosis and improve insulin sensitivity, independent of weight loss.

You do not need to lose weight to see liver benefits from exercise. Focus on getting your heart rate up (aerobic) and building muscle (resistance) regularly. Even avoiding prolonged sitting helps. The goal is to improve how your body handles energy, not just to burn calories.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, achieves greater glycemic control and weight loss compared to isolated GLP-1 receptor agonism.

For individuals with Type 2 Diabetes or obesity who need more than standard GLP-1 medications, Tirzepatide is a newer option that targets two hormone receptors (GIP and GLP-1). Clinical trials show it can lower blood sugar by more than 2% and achieve weight loss exceeding 15%, which is greater than what is typically seen with GLP-1-only drugs.

Combining resistance exercise training (RET) with adequate protein intake (≥1.2 g/kg/day) during a very low-calorie diet (VLCD) preserves skeletal muscle mass, whereas VLCD alone results in significant lean mass loss.

If you are on a strict low-calorie diet, you must lift weights and eat enough protein (at least 1.2 grams per kilogram of body weight daily) to keep your muscle. Doing just the diet without exercise or protein will cause you to lose muscle mass along with fat.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, induces substantial weight loss and improves histological markers of metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis in patients with type 2 diabetes and obesity.

If you have MASH and obesity, tirzepatide is a once-weekly injection that helps you lose weight and improves liver health markers. It starts at a low dose and increases slowly to minimize side effects. You should also follow diet and exercise advice provided by your care team.

Adhering to an ideal lifestyle (BMI <25, never smoked, moderate alcohol, ≥600 MET-min/week activity, healthy diet, 6-8h sleep) significantly reduces the risk of incident macrovascular and microvascular diseases in individuals with type 2 diabetes.

For someone with Type 2 Diabetes, focusing on six key areas—maintaining a healthy weight, never smoking, drinking moderately, exercising regularly (aiming for 600 MET-min/week), eating a balanced diet, and sleeping 6-8 hours—can significantly lower your risk of heart and kidney complications. This is not just about feeling better; it is a powerful tool to prevent serious disease progression.

Achieving a high Life’s Essential 8 (LE8) score (80-100) is associated with a substantially lower risk of incident macrovascular and microvascular diseases compared to low cardiovascular health (0-49) in individuals with Type 2 Diabetes.

Using the American Heart Association's Life’s Essential 8 framework (diet, activity, nicotine, sleep, BMI, lipids, glucose, blood pressure) to achieve a high score (80-100) can reduce your risk of heart and kidney complications by up to 80% compared to low health scores. This provides a structured, comprehensive way to manage vascular risk in Type 2 Diabetes.

Discontinuation of semaglutide or tirzepatide therapy within the first year significantly attenuates weight loss and glycemic improvement compared to continuous use, with early discontinuation yielding the poorest outcomes.

If you are using semaglutide or tirzepatide for weight loss, stopping the medication—even for a short time—significantly reduces your chances of losing weight. The data shows that people who stop early lose only 3.6% of their body weight, whereas those who stay on it lose nearly 12%. To achieve clinically meaningful results, you must maintain the prescription and reach a high maintenance dose.

Tirzepatide produces significantly greater weight loss and glycemic improvement than semaglutide when used at comparable maintenance dosages and adherence levels.

If you are choosing between Semaglutide and Tirzepatide, Tirzepatide tends to produce greater weight loss (approx. 12% vs 8% average in this study). However, this benefit is only realized if you stay on the medication. If you struggle with side effects or cost, switching drugs may not solve the problem if you end up discontinuing.

Group-based physical activity interventions, specifically those combining aerobic and resistance training, general physical activity, or mind-body exercise, significantly improve mobility-related outcomes (physical function, balance, aerobic capacity, muscle strength, and fall reduction) in community-dwelling older adults.

For older adults wanting to stay mobile, join a community group that offers a mix of cardio and strength exercises, general activity, or mind-body practices like Tai Chi. These group formats are proven to improve balance, strength, and reduce falls, and the social aspect helps you stick with it.

Adherence to a Mediterranean diet pattern, characterized by high intake of polyphenols, fiber, and healthy fats (olive oil, nuts, fish) and low intake of sugar, refined carbs, and saturated fat, provides hepatic and cardiometabolic benefits for NAFLD, even independent of weight loss.

Adopt a Mediterranean-style eating pattern: eat more vegetables, fruits, whole grains, legumes, nuts, and fish, and use olive oil. Limit red meat, processed foods, sugar, and refined carbs. You don't need to be perfect; even partial adherence helps. This pattern supports liver health and heart health simultaneously.

Regular physical activity, specifically at least 150 minutes per week of moderate aerobic exercise combined with resistance training, independently improves liver fat, prevents fibrosis and cirrhosis, and reduces mortality in NAFLD patients, even without significant weight loss.

Aim for 150 minutes of moderate exercise per week, such as brisk walking, cycling, or swimming. Add resistance training (weight lifting) if possible. Start with 30 minutes a day if 150 minutes feels overwhelming. Exercise helps your liver directly, even if the scale doesn't move much.

Consuming protein and/or fiber before carbohydrates (meal sequencing) enhances GLP-1 secretion, delays gastric emptying, and improves postprandial glucose and lipid metabolism compared to consuming carbohydrates first.

To get more out of your meals, try eating your protein and vegetables before your carbohydrates (like rice, pasta, or bread). This simple change in order triggers your gut to release more satiety hormones (GLP-1) and slows down digestion, leading to better blood sugar control and less fat storage potential.

Time-restricted eating combined with resistance training reduces fat mass to a similar extent as habitual diet combined with resistance training, without compromising fat-free mass.

If your goal is simply to lose fat while building muscle, you don't need to restrict your eating window. Eating normally throughout the day with resistance training yields the same fat loss and muscle preservation as an 8-hour eating window, provided you eat enough.

For short-term weight loss (first 6 months), dietary adherence and diet quality are primary drivers, whereas caloric restriction alone is a weaker predictor of success.

To lose weight quickly, focus on sticking to your chosen diet's rules (e.g., cutting carbs or fats) and eating high-quality foods, rather than obsessively counting calories. Adherence to the diet type predicts success better than the sheer number of calories cut.

Daily protein intake of 1.0-1.2 g/kg body weight (or 1.2-1.5 g/kg for those with chronic disease) is required to maintain muscle mass and strength in older adults, as lower intakes fail to overcome anabolic resistance.

If you are older, aim for 1.0 to 1.2 grams of protein per kilogram of your body weight every day. If you have a chronic illness like diabetes or heart disease, aim for 1.2 to 1.5 grams per kilogram. This helps your body build and keep muscle. If you have kidney disease, talk to your doctor before increasing protein.

Weight loss of 7-10% of body weight leads to significant resolution of NASH and fibrosis regression in patients with NAFLD.

To reverse fatty liver disease and NASH, you need to lose 7-10% of your body weight. If you have advanced fibrosis, aim for over 10% loss. Start with a daily calorie deficit of 500-1000 kcal and aim for at least 150 minutes of exercise per week. Even losing 3-5% helps reduce liver fat and improves insulin sensitivity, so don't wait for the full 10% to see benefits.

Achieving a weight loss of greater than 5% is independently associated with slower progression of the frailty index in adults with type 2 diabetes, regardless of HbA1c levels.

Losing more than 5% of your body weight is linked to slower physical decline in people with type 2 diabetes. This benefit holds true even if your blood sugar levels don't change drastically. Focus on sustainable weight loss through diet and exercise.

Training elbow flexors in the initial range of motion (lengthened state, 0-68 degrees) promotes greater distal biceps hypertrophy and greater full-range 1RM strength gains compared to training in the final range of motion (shortened state, 68-135 degrees).

If you are doing bicep curls, try splitting your sets: do some reps starting from a fully extended arm (lengthened position) and others from a partially flexed position. This study suggests that prioritizing the lengthened position (starting from straight arms) may lead to better muscle growth in the lower part of the bicep and greater overall strength gains than prioritizing the shortened position (starting from a flexed arm).

Prevention or delay of type 2 diabetes through intensive lifestyle intervention or metformin is associated with a lower prevalence of microvascular complications (retinopathy, nephropathy, neuropathy) compared to those who progress to diabetes.

Avoiding or delaying the onset of type 2 diabetes significantly reduces your risk of developing serious microvascular complications like eye, kidney, and nerve damage. This benefit is observed even if you don't take medication, as long as you prevent or delay diabetes.

Once-weekly subcutaneous semaglutide 2.4 mg, used as an adjunct to lifestyle intervention, significantly reduces the 10-year risk of developing type 2 diabetes in adults with overweight or obesity compared to placebo.

If you have obesity or overweight with related health issues, adding once-weekly semaglutide 2.4 mg to your lifestyle changes can significantly lower your 10-year risk of developing type 2 diabetes compared to lifestyle changes alone. This benefit is most pronounced in those with higher baseline risk or prediabetes, and maintaining the treatment appears necessary to sustain these lower risk scores.

Combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists provides additive and synergistic benefits for Cardiovascular-Kidney-Metabolic (CKM) syndrome by targeting complementary mechanisms, resulting in superior glycemic control, weight loss, and organ protection compared to monotherapy.

If you have Type 2 Diabetes, Heart Failure, Kidney Disease, or Obesity, current medical guidelines strongly support using SGLT2 inhibitors and GLP-1 receptor agonists, either alone or together, to protect your heart and kidneys. These drugs work through different mechanisms to lower blood sugar, reduce weight, and protect organs. While they can be expensive and hard to access, they are considered first-line treatments for high-risk patients. Talk to your doctor about whether combination therapy is appropriate for your specific risk profile, especially if single medications aren't enough.

Dual GLP-1/GIP receptor agonists (e.g., tirzepatide) and multi-agonists (e.g., retatrutide) produce superior weight loss compared to single GLP-1 receptor agonists by synergistically enhancing anorectic effects in the CNS and reducing emetogenic side effects.

If current GLP-1 therapy is ineffective or causes intolerable nausea, discuss dual (GLP-1/GIP) or multi-agonists (GLP-1/GIP/Glucagon) with your provider. These newer agents target multiple pathways to potentially yield greater weight loss and fewer GI side effects.